Table 1.
Patient demographics. Abbreviations: NP = no pathological abnormality; PMI = post‐mortem interval; y = years; h = hours; M = male; F = female
| Case# | Sex | Braak and Braak stage | APOE status | CR1 status§ | Age (y) | PMI (h) |
|---|---|---|---|---|---|---|
| Controls | ||||||
| 1 | F | NP | ε3/ε4 | A/G | 47 | 7 |
| 2 | F | NP | ε3/ε3 | A/G | 42 | 22 |
| 3 | F | NP | ε3/ε3 | A/G | 81 | 23 |
| 4 | M | NP | ε3/ε3 | A/G | 70 | 23 |
| AD only | ||||||
| 5 | M | VI | ε3/ε4 | A/G | 80 | 22 |
| 6 | F | VI | ε3/ε3 | A/G | 81 | 6.5 |
| 7 | M | VI | ε3/ε3 | A/G | 89 | 15 |
| 8 | M | VI | ε3/ε4 | A/A | 81 | 9.5 |
| AD mild CAA | ||||||
| 9 | F | V | ε3/ε3 | A/G | 79 | 6 |
| 10 | F | V/VI | ε3/ε3 | A/A | 91 | 3.5 |
| 11 | F | VI | ε3/ε3 | A/G | 89 | 24 |
| 12 | M | V/VI | ε3/ε3 | A/A | 82 | 16 |
| 13 | F | VI | ε3/ε4 | A/A | 97 | 12 |
| 14 | F | VI | ε3/ε3 | A/A | 73 | 13 |
| 15 | F | VI | ε3/ε4 | A/G | 81 | 24 |
| 16 | M | VI | ε3/ε3 | A/A | 95 | 22 |
| AD moderate CAA | ||||||
| 17 | M | V/VI | ε3/ε3 | A/A | 82 | 5 |
| 18 | F | VI | ε3/ε3 | A/A | 96 | 7 |
| 19 | F | VI | ε3/ε3 | A/A | 81 | 11 |
| 20 | M | VI | — | — | 83 | 12 |
| AD severe CAA | ||||||
| 21 | F | VI | ε3/ε4 | A/A | 88 | 38 |
| 22 | F | VI | ε4/ε4 | A/A | 71 | 20 |
| 23 | F | VI | ε3/ε3 | A/A | 83 | 6 |
| 24 | F | VI | ε3/ε3 | A/A | 69 | 18 |
§The CR1 A/A allele was significantly associated with CAA cases vs. non‐CAA cases, P = 0.006.